MTOR and hepatocellular carcinoma: Our data indicated that combining the IGFR inhibitor NVP-AEW541 with inhibitors against PI3K/Akt/mTOR pathway (MK2206 or BEZ235) results in synergistic anti-tumor effects in HCC cells in vitro and in vivo.